AdvanTIG-206: Phase II Randomized Open-Label Study of Ociperlimab (OCI) Plus Tislelizumab (TIS)+BAT1706 (bevacizumab Biosimilar) Versus TIS+BAT1706 in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC)

Z. Ren,Y. Huang,Y. Guo, M. M. Hou, W. Wang,M. Kuang, C. Hao, Y. Zhang,T. Song,C. Dai, K. Hsing-Tao,V. Li,R. Abdrashitov, L. Wang, J. Fan

ANNALS OF ONCOLOGY（2023）

Cited 0|Views0

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined